Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer.


AIMS To determine the maximum tolerated dose (MTD), safety and anti-tumor activity of afatinib combined with docetaxel in advanced cancer. PATIENTS & METHODS The MTD was determined from dose-limiting toxicities in the first cycle. RESULTS Thirty-one patients received 10, 20 and 30 mg oral afatinib, plus 60 and 75 mg/m(2) intravenous docetaxel (six… (More)
DOI: 10.2217/fon.12.195


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.